Abstract CT226: Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma …

J Muzaffar, K Kirtane, R Redman, MH Yang, TM Kim… - Cancer Research, 2024 - AACR
Abstract BACKGROUND: FLX475 (tivumecirnon) is a selective CCR4 antagonist designed
to block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor …
相关文章

Phase 1/2 study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer

CC Lin, T Kim, P Desai, K Lee, YH Feng… - Annals of …, 2022 - rapt.com
Background: Preclinical studies with oral CCR4 antagonists have demonstrated inhibition of
suppressive regulatory T cell (T reg) migration into the tumor microenvironment and …
被引用次数：2 相关文章 所有 2 个版本
[HTML] bmj.com

[HTML][HTML] 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not …

TM Kim, N Ngamphaiboon, KH Lee, P Desai, CC Lin… - 2023 - jitc.bmj.com
Background FLX475 (tivumecirnon) is a selective CCR4 antagonist designed to block the
recruitment of immunosuppressive regulatory T cells (T reg) into the tumor …
相关文章
[HTML] esmoiotech.org

[HTML][HTML] 187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer

CC Lin, TM Kim, P Desai, KH Lee, YH Feng… - Immuno-Oncology …, 2022 - esmoiotech.org
Background Preclinical studies with oral CCR4 antagonists have demonstrated inhibition of
suppressive regulatory T cell (T reg) migration into the tumor microenvironment and …
相关文章

Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.

DG Brockstedt, A Grant, J Adamik, D Trujillo, RK Goyal… - 2023 - ascopubs.org
2625 Background: FLX475 is a potent and selective CCR4 antagonist, designed to block the
recruitment of immunosuppressive regulatory T cells (Treg) into tumors without affecting …
被引用次数：2 相关文章

Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).

J Bauml, TY Seiwert, DG Pfister, FP Worden, SV Liu… - 2016 - ascopubs.org
6011 Background: Current treatment options for patients (pts) with recurrent/metastatic (R/M)
HNSCC who progress on platinum and cetuximab have very limited efficacy …
被引用次数：37 相关文章

CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001+ pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

DJL Wong, A Panwar, A Rosenberg, V Karivedu… - 2021 - ascopubs.org
TPS6089 Background: PD-1 blockade±chemotherapy has recently become a primary
systemic therapy recommended by NCCN guidelines for patients (pts) with recurrent or …
被引用次数：1 相关文章

Abstract CT236: INTERLINK-1: a phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in …

J Fayette, T Seiwert, RL Ferris, K Harrington, R Haddad… - Cancer Research, 2022 - AACR
Background: Head and neck (HN) cancer is the 7th most common cancer and 7th leading
cause of cancer death worldwide with approximately 930,000 new cases and 470,000 …
被引用次数：1 相关文章

926P UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)

I Vasiliadou, D Grose, A Hartley… - Annals of …, 2023 - annalsofoncology.org
Background Immunotherapy has significantly improved survival in patients with several solid
tumours including head and neck squamous cell carcinoma (HNSCC). Pembrolizumab …
相关文章

342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

CJ Yen, A Klochikhin, E Cohen… - Annals of …, 2015 - annalsofoncology.org
Background: Cetuximab plus platinum and 5-fluorouracil (5-FU) is the only combination
regimen recommended by current guidelines as the first-line treatment of recurrent or …
被引用次数：2 相关文章